August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Bevacizumab plus Chemotherapy Approved for Several Types of Ovarian Cancer

FDA Approvals, News & Updates

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Keytruda Receives 2 New Indications: Metastatic Cervical Cancer and Relapsed Mediastinal Large B-Cell Lymphoma

FDA Approvals, News & Updates

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Venclexta Indicated for CLL or SLL, Alone or in Combination with Rituxan

FDA Approvals, News & Updates

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Tafinlar-Mekinist Combination Approved for Metastatic Thyroid Cancer with BRAF V600E Mutation

FDA Approvals, News & Updates

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Kymriah Approved for Adults with Relapsed or Refractory Large B-Cell Lymphoma

FDA Approvals, News & Updates

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma

By Wayne Kuznar

Clinical Trials, Multiple Myeloma, Hematologic Malignancies, Personalized Medicine

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma

By Phoebe Starr

Hematologic Malignancies, Leukemia

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Next-Generation Sequencing Could Help Treatment Decisions in Acute Myeloid Leukemia

Leukemia, Hematologic Malignancies

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Timing of Palliative Care Consults Affects Healthcare Utilization in Elderly Patients with Pancreatic Cancer

Pancreatic Cancer

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected

By Wayne Kuznar

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Based on results of a study presented at ASCO 2018, the presence of an MSI-H or dMMR tumor signature, regardless of cancer type or family history, should prompt genetic testing to evaluate for Lynch syndrome.

Page 1 of 3

1
2
3

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

VBCC Print Edition

VBCC Weekly e‑Newsletter

I have reviewed and consent to the terms of VBCC's Privacy Policy, and VBCC has my permission to retain my information in its database, and to forward pertinent communications to me.